{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T02:50:39Z","timestamp":1786589439412,"version":"build-2736575974"},"reference-count":14,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jcf.2023.04.019","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:39:00Z","timestamp":1683074340000},"page":"843-846","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Impact of elexacaftor\/tezacaftor\/ivacaftor on fat-soluble vitamin levels in children with cystic fibrosis"],"prefix":"10.1016","volume":"22","author":[{"given":"L","family":"Schembri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Warraich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7743-3283","authenticated-orcid":false,"given":"S","family":"Bentley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0580-2478","authenticated-orcid":false,"given":"SB","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0754-3863","authenticated-orcid":false,"given":"IM","family":"Balfour-Lynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2023.04.019_bib0001","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.clnu.2016.03.004","article-title":"ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis","volume":"35","author":"Turck","year":"2016","journal-title":"Clin Nutr"},{"issue":"Suppl 38","key":"10.1016\/j.jcf.2023.04.019_bib0002","first-page":"14","article-title":"The role of vitamins in cystic fibrosis","volume":"93","author":"Carr","year":"2000","journal-title":"J R Soc Med"},{"key":"10.1016\/j.jcf.2023.04.019_bib0003","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/ncp.10899","article-title":"Update on the management of vitamins and minerals in cystic fibrosis","volume":"37","author":"Sankararaman","year":"2022","journal-title":"Nutr Clin Pract"},{"key":"10.1016\/j.jcf.2023.04.019_bib0004","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.3390\/nu13092907","article-title":"The impact of highly effective CFTR modulators on growth and nutrition status","volume":"13","author":"Bass","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.jcf.2023.04.019_bib0005","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3390\/antiox10030483","article-title":"CFTR modulator therapy with Lumacaftor\/Ivacaftor alters plasma concentrations of lipid-soluble vitamins A and E in patients with cystic fibrosis","volume":"10","author":"Sommerburg","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.jcf.2023.04.019_bib0006","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1164\/rccm.201906-1227OC","article-title":"Real-life safety and effectiveness of Lumacaftor-Ivacaftor in patients with cystic fibrosis","volume":"201","author":"Burgel","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2023.04.019_bib0007","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/clinchem\/43.1.146","article-title":"Reference values for plasma concentrations of vitamin E and A and carotenoids in a Swiss population from infancy to adulthood, adjusted for seasonal influences","volume":"43","author":"Winklhofer-Roob","year":"1997","journal-title":"Clin Chem"},{"key":"10.1016\/j.jcf.2023.04.019_bib0008","unstructured":"NICE Clinical Knowledge Summary. Vitamin D deficiency in children. https:\/\/cks.nice.org.uk\/topics\/vitamin-D-deficiency-in-children\/. Last revised January 2022. [Accessed 29 March 2023]."},{"key":"10.1016\/j.jcf.2023.04.019_bib0009","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study","volume":"4","author":"Davies","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2023.04.019_bib0010","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/ppul.25781","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on vitamin D absorption in cystic fibrosis patients","volume":"57","author":"Wright","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2023.04.019_bib0011","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/S1569-1993(21)01639-8","article-title":"Improvement in fat-soluble vitamin levels following highly effective CFTR modulator use in children with CF","volume":"20","author":"Kuffel","year":"2021","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2023.04.019_bib0012","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.jcjo.2021.04.018","article-title":"Papilledema and hypervitaminosis A after elexacaftor\/tezacaftor\/ivacaftor for cystic fibrosis","volume":"57","author":"Miller","year":"2022","journal-title":"Canadian J Ophthalm"},{"key":"10.1016\/j.jcf.2023.04.019_bib0013","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/j.jcf.2022.01.010","article-title":"Hypervitaminosis A with fulminant secondary intracranial hypertension following personalized medicine-based Elexacaftor\/Tezacaftor\/Ivacaftor initiation in a preadolescent with cystic fibrosis","volume":"21","author":"Wisniewski","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.04.019_bib0014","series-title":"Clinical guidelines: care of children with cystic fibrosis","year":"2023"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932300125X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932300125X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T08:17:33Z","timestamp":1756714653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156919932300125X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S156919932300125X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.04.019","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of elexacaftor\/tezacaftor\/ivacaftor on fat-soluble vitamin levels in children with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}